---

Home    List your patent    My account     Help     Support us    

---

Antagonists for the Treatment of Immune Suppressed Diseases

[Category : - HEALTH]
[Viewed 57 times]

The CA125/MUC16 protein has been found to be a suppressor of antibody-mediated humoral immunity and antibody-drug conjugate (ADC) cytotoxicity. The generation of antagonists that can block its immunosuppressive effects on antibodies and ADCs may lead to enhanced therapeutic responses that are negatively impacted by CA125/MUC16. In addition, they offer the ability to unlock humoral immune suppression of patients treated with antibody-based therapeutics, especially those afflicted with immunological disorders and cancer.

This internationally filed patent covers the composition-of-matter and use of a high-affinity CA125 antagonist, named NAV-005, for the treatment of patients with CA125-positive disease. NAV-005 is a unique IgG1 fusion protein that binds to CA125 with high affinity and antagonizes its humoral immunosuppressive effects on antibodies targeting disease-associated cells as well as ADCs to which CA125 binds and reduces internalization of target cells, a requirement for maximal ADC cytotoxicity.

The patent has been granted in Japan and China and is in late-stage processing in North America and the EU.

---

---

---

---

[ Home | List a patent | Manage your account | F.A.Q.|Terms of use | Contact us]

Copyright PatentAuction.com 2004-2017
Page created at 2025-11-26 2:20:01, Patent Auction Time.